Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 in Patients with Clear Cell Renal Cell Carcinoma

NEXT STORY
OpGen Announces Publication of Final Study Results of Unyvero HPN Panel for Diagnosis of Bacterial Co-Infections in ICU Patients with COVID-19 Pneumonia
PREV STORY
Insights on the Nephrology Devices Global Market to 2025 – Impact of COVID-19 with Ansoff Analysis
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Data from Investigator-sponsored Trial of Mereo BioPharma’s alvelestat in Bronchiolitis Obliterans Syndrome (BOS) Accepted for Presentation at American Society of Hematology (ASH) Annual Meeting

author_avatar
NASDAQ Market News

BeiGene Announces First Patient Dosing in China with Investigational PARP Inhibitor BGB-290

BEIJING, Dec. 21, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company ...

author_avatar
NASDAQ Market News

Avadel Pharmaceuticals to Report Second Quarter 2017 Results

DUBLIN, Ireland, July 20, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), today announced ...

author_avatar
NASDAQ Market News